SCHEMBL18763512

SCHEMBL18763512

CC(C)(CO)c1cc(NC(=O)O)no1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.51
NPC1 O15118 5/20 0.48
RAB9A P51151 4/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
HPGD P15428 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
PKM P14618 1/20 0.45
TSHR P16473 1/20 0.45
HTT P42858 1/20 0.45
MAPK14 Q16539 3/20 0.43
FLT3 P36888 3/20 0.42
GAA P10253 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MAPK13 O15264 1/20 0.41
RAF1 P04049 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9893035 0.87 EGFR (0.51) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL12155319 0.86 EGFR (0.50) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL9893113 0.84 EGFR (0.56) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL9891820 0.84 EGFR (0.49) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL1758718 0.83 EGFR (0.66) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL27218027 0.80 NPC1 (0.50) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL770045 0.80 RAF1 (0.50) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL1698936 0.79 EGFR (0.50) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL1078864 0.77 NPC1 (0.48) EGFRNPC1RAB9AKMT2AMEN1
SCHEMBL1256289 0.76 GAPDH (0.51) EGFRNPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3169671-B1 1-(5-(TERT.-BUTYL)ISOXAZOL-3-YL)-3-(4-((PHENYL)ETHYNYL)PHENYL)UREA DERIVATIVES AND RELATED COMPOUNDS AS FLT3 INHIBITORS FOR TREATING CANCER SUNSHINE LAKE PHARMA CO LTD (CN) 2019-08-21 EP disclosed
US-10065934-B2 Substituted urea derivatives and pharmaceutical uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-09-04 US disclosed
US-20170114032-A1 SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114032-A1 SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF ULK2, ULK3, ULK1 EGFR 1150/4885NPC1 1201/4885RAB9A 1735/4885
US-10065934-B2 Substituted urea derivatives and pharmaceutical uses thereof ULK2, ULK3, ULK1 EGFR 1150/4885NPC1 1201/4885RAB9A 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.